Xulane Patch
Product Images NDC 50090-1683

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Xulane (NDC 50090-1683). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Vte Risk Of Norelgestromin And Ethinyl Estradiol Transdermal System Relative To Combined Oral Contraceptives (Image 01)

This text provides information on different methods of birth control, including implants, injections, intrauterine devices, birth control pills, skin patches, vaginal rings with hormones, condoms, diaphragms, spermicide, withdrawal, and abstaining from sex on fertile days of the monthly cycle. It also discusses the varying number of pregnancies per 100 women in one year based on the birth control method used.*

FDA Label Image

Figure 5: Mean Serum Concentration-time Profiles Of Ngmn Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 02)

FDA Label Image

Image 03

FDA Label Image

Figure 6: Mean Serum Concentration-time Profiles Of Ee Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 04)

FDA Label Image

Norelgestromin And Ethinyl Estradiol Structural Formulas (Image 05)

FDA Label Image

Image 06

FDA Label Image

Image 07

This is a chart outlining the ranges of blood clot occurrences per 10,000 woman-years based on different user categories (CHC user, Pregnant, Postpartum). It specifies that the data for pregnancy is based on actual duration of pregnancy in reference studies. The abbreviation "CHC" stands for combination hormonal contraception. The chart seems to provide information on the incidence rates of blood clots for different groups of women.*

FDA Label Image

Image 08

FDA Label Image

Image 09

FDA Label Image

Image 10

FDA Label Image

Image 11

FDA Label Image

Image 12

FDA Label Image

Image 14

FDA Label Image

Image 15

This text provides information on postpartum contraception, specifically highlighting the use of combination hormonal contraception (CHC) for mothers 13 weeks postpartum. The data on pregnancy rates is based on actual pregnancy durations rather than a standard assumption of nine months. The text mentions a pregnancy rate of 7 to 27 per 10,000 women-years using this model.*

FDA Label Image

Image 16

FDA Label Image

Image 17

FDA Label Image

Image 18

FDA Label Image

Image 19

FDA Label Image

Image 20

FDA Label Image

Image 21

FDA Label Image

Image 22

FDA Label Image

Label Image (Lbl500901683)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.